{
  "source": "PA-Med-Nec-Siliq.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2126-15\nProgram Prior Authorization/Medical Necessity\nMedication Siliq (brodalumab)*\n*Siliq is excluded from coverage for the majority of our benefits\nP&T Approval Date 5/2017, 2/2018, 2/2019, 9/2019, 5/2020, 5/2021, 6/2021, 12/2021,\n5/2022, 11/2022, 1/2023, 4/2023, 7/2023, 10/2024, 4/2025\nEffective Date 6/1/2025\n1. Background:\nSiliq (brodalumab) is a human interleukin-17 receptor A (IL-17RA) antagonist indicated\nfor the treatment of moderate to severe plaque psoriasis in adult patients who are candidates\nfor systemic therapy or phototherapy and have failed to respond or have lost response to\nother systemic therapies.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\na. Siliq will be approved based on the following criteria:\n(1) Submission of medical records (e.g., chart notes, laboratory values, prescription\nclaims history) documenting all of the following:\n(a) Diagnosis of chronic moderate to severe plaque psoriasis\n-AND-\n(b) One of the following:\ni. All of the following:\n1. Greater than or equal to 3% body surface area involvement,\npalmoplantar, facial, genital involvement, or severe scalp psoriasis\n-AND-\n2. History of failure to one of the following topical therapies, unless\ncontraindicated or clinically significant adverse effects are\nexperienced (document drug, date, and duration of trial):\n Corticosteroids (e.g., betamethasone, clobetasol, desonide)\n Vitamin D analogs (e.g., calcitriol, calcipotriene)\n Tazarotene\n Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\n Anthralin\n© 2025 UnitedHealthcare Services Inc.\n1\n Coal tar\n-AND-\n3. History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document drug, date, and duration of trial)b^\n-OR-\nii. Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of plaque psoriasis as documented by",
    "erienced (document drug, date, and duration of trial)b^\n-OR-\nii. Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of plaque psoriasis as documented by\nclaims history or submission of medical records (Document drug, date,\nand duration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla\n(apremilast), Skyrizi (risankizumab), ustekinumab, Tremfya\n(guselkumab), Enbrel (etanercept)].\n-AND-\n(c) History of failure, contraindication, or intolerance to three of the following\npreferred products (document drug, date, and duration of trial):^\ni. One of the preferred adalimumab productsc\nii. Cimzia (certolizumab)\niii. Cosentyx (secukinumab)\niv. Enbrel (etanercept)\nv. Skyrizi (risankizumab)\nvi. Sotyktu (deucravacitinib)\nvii. One of the preferred ustekinumab productsc\nviii. Tremfya (guselkumab)\n-AND-\n(d) Patient is not receiving Siliq in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\n-AND-\n(e) Prescribed by or in consultation with a dermatologist\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n© 2025 UnitedHealthcare Services Inc.\n2\nc For a list of preferred products please reference drug coverage tools.\n^Tried/failed alternative(s) are supported by FDA labeling.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous clai",
    "lternative(s) are supported by FDA labeling.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• *Siliq is excluded from coverage for the majority of our benefits\n• Supply limits may be in place.\n4. References:\n1. Siliq [package insert]. Bridgewater, NJ: Bausch Health US, LLC; April 2020.\n2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the\ntreatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.\n3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of\npsoriasis and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for\ntreatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.\n4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of\npsoriasis with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and\nphotochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.\n6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with\ntraditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.\n7. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care\nfor the management of psoriasis and psoriatic arthritis: section 6. Guidel",
    "J Am Acad Dermatol 2009;61(3):451-85.\n7. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care\nfor the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the\ntreatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based\nconclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-74.\n8. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris –\nupdate 2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm\nVenereol 2015;29:2277-94.\n9. Menter A, Strober BE, Kaplan DH et al. Joint AAD-NPF guidelines of care for the\nmanagement and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019:80:1029-\n72.\nProgram Prior Authorization/Medical Necessity-Siliq (brodalumab)\nChange Control\nDate Change\n5/2017 New Program.\n2/2018 Updated criteria, adding Tremfya as an additional preferred agent for\nplaque psoriasis.\n2/2019 Annual review. Added manufacturer assistance program information.\nUpdated background. Addition of Cimzia as preferred agent.\n© 2025 UnitedHealthcare Services Inc.\n3\n9/2019 Updated criteria adding Skyrizi as preferred medication. Added\ncoverage exclusion statement. Updated references.\n5/2020 Updated formatting without change to clinical intent.\n5/2021 Annual review. Removed drug documentation where only one drug is\nrequired. Updated references.\n6/2021 Added coverage criteria for patients previously treated with a biologic\nDMARD.\n12/2021 Updated the following with no change to clinical intent: updated\nconventional DMARD bypass language for psoriasis, removed\n“biologic” from required preferred product criteria language and\nupdated CT/KY footnote.\n5/2022 Updated with Tried/failed alternative(s) are supported by FDA labeling\nfootnote. Added Mississippi to state mandate.\n11/2022 Added Enbrel as a preferred product step option. Added Enbrel as an\nexample where appropriate.\n1/2023 Updated step therapy requirements to Humira or Amjevi",
    " Added Mississippi to state mandate.\n11/2022 Added Enbrel as a preferred product step option. Added Enbrel as an\nexample where appropriate.\n1/2023 Updated step therapy requirements to Humira or Amjevita. Updated\nlisted examples from Humira to adalimumab.\n4/2023 Updated step therapy requirement from Humira or Amjevita to one of\nthe preferred adalimumab products and added the footnote “For a list of\npreferred adalimumab products please reference drug coverage tools.”\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Updated step requirement noting Adalimumab-adaz (unbranded\nHyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab\nproducts with no change to clinical intent. Removed preferred\nadalimumab footnote. Added Sotyktu as step therapy agent. Moved\nCosentyx to preferred step agent and changed step to three agents.\nUpdated state mandate footnote.\n4/2025 Removed examples for adalimumab in step therapy. Changed Stelara\nstep therapy to “One of the preferred ustekinumab productsc”. Changed\nStelara example to Ustekinumab. Added the footnote “For a list of\npreferred products please reference drug coverage tools.”\n© 2025 UnitedHealthcare Services Inc.\n4"
  ]
}